Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

188.67 +4.79 (+2.60%)
Delayed Quote Updated: 9:35 AM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 Next >
News headline image
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
From AstraZeneca
Via Business Wire
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
News Provided by USA News Group on behalf of MindWalk Holdings Corp. 
From USA News Group
Via GlobeNewswire
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
From AstraZeneca
Via Business Wire
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think. 
Via The Motley Fool
News headline image
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? ↗
There's a good reason why AstraZeneca tanked when merger rumors hit the Street. 
Via The Motley Fool
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Astrazeneca Q2 Earnings Call Highlights ↗
Astrazeneca (NYSE:AZN) reported first-half 2026 revenue growth of 6% at constant exchange rates, or 11% excluding the effects of generic competition on Farxiga and Brilinta, while core earnings per... 
Via MarketBeat
Topics ETFs Earnings
News headline image
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca results: H1 and Q2 2026
From AstraZeneca
Via Business Wire
News headline image
AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AstraZeneca PLC- AZN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
From Pomerantz LLP
Via GlobeNewswire
News headline image
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals. 
Via MarketBeat
News headline image
AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage ↗
Astrazeneca (NYSE:AZN) told investors and analysts that it is continuing to embed sustainability into its business strategy while updating some of its 2030 targets to reflect growth and lessons learned... 
Via MarketBeat
Topics Artificial Intelligence Climate Change ETFs
News headline image
IEFA vs. VXUS: Both Are Cheap. Both Are Broad. Here Is the Key Difference Long-Term Investors Need to Understand. ↗
These international stock ETFs from iShares and Vanguard are very different once you look under the surface. 
Via The Motley Fool
Topics ETFs
News headline image
AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
From AstraZeneca
Via Business Wire
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
Via Investor Brand Network
News headline image
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
From AstraZeneca
Via Business Wire
News headline image
IXUS vs. IEFA: Which International ETF Is Better for Most Investors? ↗
When buying international ETFs, owning more stocks in more countries might be a better bet. 
Via The Motley Fool
Topics ETFs
News headline image
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
From AstraZeneca
Via Business Wire
News headline image
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
News headline image
Marathon Halves Its Copa Stake—The Panama Hub Advantage Still Stands ↗
Panama-based Copa Holdings operates a major airline network across the Americas, serving both passenger and cargo markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
From AstraZeneca
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.